Bausch Health Companies Inc., a global, diversified pharmaceutical company, has completed its previously announced tender offer to acquire Durect Corporation. Under the terms of the agreement, Bausch Health acquired all outstanding shares of Durect for $1.75 per share in cash, representing a total upfront cash payment of approximately $63 million at closing. The transaction also includes the potential for two additional net sales milestone payments of up to $350 million in the aggregate (subj...